cycloaddit
gener
aspect
nh
nh
oh
ho
scheme
synthet
strategi
zanamivirlik
compound
b
cycloaddit
reaction
antivir
compound
chapter
cycloaddit
reaction
whose
applic
main
topic
present
book
classic
classifi
within
group
pericycl
reaction
exhaust
studi
mani
research
group
last
year
investig
pursu
basi
experiment
research
upon
theoret
methodolog
base
ab
initio
calcul
evolut
theori
use
increasingli
power
comput
softwar
increas
level
theori
appli
complex
molecular
system
electron
densiti
analysi
propos
domingo
molecular
electron
densiti
theori
promis
go
deep
cycloaddit
reaction
mechan
method
seem
offer
novel
opportun
respect
studi
base
simpl
molecular
orbit
mo
interact
well
frontier
mo
fmo
theori
typic
employ
last
centuri
new
theoret
investig
base
accur
experiment
studi
built
new
solid
reactiv
model
relev
type
organ
reaction
allow
profound
ration
new
find
impli
strong
signific
repercuss
cycloaddit
reaction
applic
modern
organ
chemistri
synthesi
specif
matter
quit
complex
discuss
appear
literatur
next
year
level
complex
theoret
investig
increas
develop
new
comput
cluster
complex
matter
regard
mechan
potenti
synthet
applic
cycloaddit
reaction
still
constantli
discuss
literatur
level
complex
theoret
investig
solut
demand
increas
synthesi
molecul
high
level
complex
increas
import
mainli
medicin
chemistri
field
place
topic
cycloaddit
front
dichotomi
use
particip
pivot
step
synthesi
releg
simpl
chemic
curios
applic
solv
tremend
need
modern
organ
chemistri
sever
book
review
publish
late
nowaday
deal
gener
specif
aspect
cycloaddit
chemistri
cycloaddit
reaction
matur
topic
organ
chemistri
abundantli
use
differ
area
chemistri
repres
pivot
step
reach
desir
target
book
dedic
cycloaddit
reaction
deal
typic
synthesi
heterocycl
gener
organ
synthesi
applic
specif
applic
natur
product
synthesi
describ
use
class
organ
compound
partner
cycloaddit
reaction
book
appear
topic
current
chemistri
collect
deal
bioorthogon
chemistri
edit
vrabel
carrel
repres
first
exampl
book
dedic
view
cycloaddit
modern
organ
chemistri
howev
subject
still
demand
gener
review
sinc
recent
year
pericycl
reaction
extens
appli
differ
chemistri
area
chemic
biolog
biolog
process
catalyz
cycloaddit
reaction
deliveri
antivir
anticanc
drug
target
biolog
activ
molecul
materi
chemistri
applic
medicin
photovolta
process
photochemistri
energi
harvest
none
topic
cycloaddit
reaction
spread
receiv
unifi
overview
singl
book
could
offer
solid
background
futur
develop
subject
moreov
chronolog
structur
refer
regard
gener
topic
allow
reader
recogn
relev
specif
subject
past
decad
evolut
synthesi
respect
specif
activ
compound
book
aim
fill
gap
shed
new
light
pericycl
reaction
demonstr
valuabl
tool
may
elegantli
solv
synthet
mechanist
problem
modern
organ
chemistri
da
reaction
one
gener
class
cycloaddit
includ
also
hetero
da
hda
reaction
cycloaddit
cycloaddit
reaction
fig
within
frame
interand
intramolecular
version
reaction
wide
use
organ
synthesi
mani
case
reaction
occur
room
temperatur
harsher
reaction
condit
sometim
requir
get
final
compound
moreov
use
catalyst
increasingli
develop
way
acceler
reaction
mainli
ensur
enantioselect
diasteroselect
process
da
reaction
involv
dien
bear
electrondon
substitu
electronpoor
dienophil
howev
da
exist
also
invers
electron
demand
version
substitu
locat
dien
dienophil
display
revers
electron
properti
respect
classic
da
reaction
two
cycloaddend
must
complementari
electron
charact
ensur
use
da
cycloaddit
reaction
fig
monument
work
rolf
huisgen
et
al
led
gener
concept
cycloaddit
reaction
extrem
valuabl
synthet
tool
permit
prepar
molecul
higher
complex
reactant
reaction
rival
process
synthet
util
mainli
field
heterocycl
chemistri
fivememb
heterocycl
synthet
target
reaction
abil
produc
heterocycl
extend
import
cycloaddit
area
organ
chemistri
strictli
relat
ring
format
process
moreov
introduct
new
chiral
catalyst
allow
control
new
stereocent
deriv
cycloaddit
reaction
valuabl
stereochem
outcom
born
newli
synthes
molecul
molecul
drug
key
point
determin
success
synthet
approach
mechan
reactiv
select
reaction
complet
ration
accord
modern
theoret
investig
howev
tradit
refer
concept
still
use
illustr
basic
idea
background
subject
treat
book
figur
scheme
focu
reader
attent
pivot
step
synthes
highlight
role
cycloaddit
reaction
achiev
best
result
term
chemic
yield
select
term
biolog
activ
smallest
simplest
biolog
structur
call
viru
latin
poison
lack
type
cellular
organ
forc
live
within
cell
intracellular
parasit
viral
infect
deepli
mark
human
histori
spanish
conquest
south
american
territori
show
paradigmat
pictur
death
develop
new
power
diagnost
methodolog
allow
increas
capac
identifi
new
virus
forward
new
frighten
hemorrhag
african
fever
discov
attribut
filovirus
aid
appear
although
hiv
alreadi
present
human
popul
anoth
emerg
reappear
viral
infect
due
viru
mutat
resist
antivir
therapi
case
influenza
virus
viru
surfac
protein
chang
recogniz
human
immun
system
longer
sometim
viru
genoma
exchang
human
anim
back
human
determin
new
pandem
situat
social
alarm
viral
infect
quit
detriment
sinc
contrari
bacteria
virus
defeat
antibiot
recent
small
number
antivir
compound
could
use
pharmacolog
treatment
diseas
luckili
virus
progress
chemic
research
synthet
approach
new
power
method
contrast
viral
infect
demand
antivir
compound
constantli
increas
chemistri
constantli
examin
furnish
novel
strategi
largescal
prepar
activ
molecul
start
discuss
applic
da
cycloaddit
synthesi
valuead
molecul
worth
cite
case
influenza
virus
specif
viru
neuraminidas
na
inhibitor
prepar
differ
synthet
approach
common
pivot
step
repres
da
cycloaddit
reaction
research
subject
offer
also
brilliant
exampl
joint
effort
academia
pharmaceut
industri
influenza
infect
known
seriou
health
concern
caus
morbid
mortal
mani
countri
current
option
treatment
prevent
sometim
sever
limit
underscor
need
new
effect
antiinfluenza
agent
influenza
na
one
two
major
surfac
glycoprotein
express
influenza
virus
na
promot
cleavag
termin
sialic
acid
residu
attach
glycoprotein
glycolipid
therefor
na
repres
potenti
target
develop
antiinfluenza
agent
fact
merg
research
group
gilead
scienc
inc
roch
discoveri
propos
synthesi
deriv
epim
possess
side
chain
similar
compound
compound
synthes
via
hda
reaction
evalu
influenza
na
inhibitor
compound
exhibit
rang
influenza
na
inhibitori
activ
strategi
follow
base
hda
cycloaddit
reaction
hydrazon
alken
presenc
sodium
carbon
acetonitril
afford
mixtur
desir
cycloadduct
regioisom
yield
scheme
remov
boc
group
saponif
amino
compound
could
easili
separ
regioisom
simpl
chromatographi
influenza
na
inhibitori
activ
compound
report
scheme
compound
similar
side
chain
stereochemistri
tran
exhibit
ic
influenza
influenza
b
increas
activ
result
convert
amino
group
guanidin
function
rel
weak
na
inhibitori
activ
compar
explain
conform
bind
studi
investig
reveal
nh
nhac
group
occupi
pseudoaxi
posit
rather
normal
prefer
pseudoequatori
posit
adopt
bind
influenza
na
indic
energi
penalti
incur
upon
bind
addit
xray
structur
bound
na
reveal
differ
bind
mode
side
chain
compar
case
two
ethyl
group
side
chain
bind
two
differ
pocket
howev
presum
owe
partli
planar
natur
amid
bond
side
chain
poorli
fit
expos
hydrophob
group
water
fruit
collabor
univers
manchest
research
group
big
chemic
compani
glaxosmithklin
establish
synthesi
new
inhibitor
influenza
viru
sialidas
structur
relat
cyclohexen
deriv
zanamivir
administ
prodrug
form
oseltamivir
known
interfer
viral
replic
act
potent
inhibitor
viru
sialidas
enzym
locat
viral
surfac
cleav
bond
acid
sialic
acid
scheme
synthet
strategi
acid
termin
sialic
acid
residu
zanamivir
bind
activ
site
sialidas
analog
manner
wherea
trihydroxypropyl
side
chain
bind
hydrophil
pocket
via
hydrogen
bond
interact
pentyloxi
function
accommod
hydrophob
pocket
import
substitu
structur
demonstr
sever
bind
studi
structur
modif
replac
select
substitu
aim
tune
properli
inhibitori
activ
exampl
replac
trihydroxypropyl
side
chain
dialkylcarbamoyl
entiti
lead
compound
retain
potenc
influenza
sialidas
lose
effect
influenza
b
sialidas
surprisingli
seri
guanidino
function
appear
play
role
bind
influenza
sialidas
also
locat
cqc
doubl
bond
seem
critic
retrosynthet
analysi
take
account
gener
regioisom
synthesi
two
novel
compound
whose
inhibit
activ
evalu
comparison
base
upon
da
tactic
nitro
acrylamid
dien
scheme
reaction
afford
separ
mixtur
regioisomer
cycloadduct
b
overal
yield
synthesi
proce
use
regioisom
reduc
al
hg
acetyl
give
subsequ
transform
three
step
ester
yield
mixtur
diastereoisom
ratio
martin
sulfuran
dehydr
reaction
provid
mixtur
compound
yield
chromatographi
final
hydrolysi
ester
lioh
h
unev
lead
desir
acid
yield
similar
condit
ester
afford
mixtur
product
preval
compon
isol
nearpur
state
syrup
yield
addit
etoac
mixtur
decant
liquid
identifi
requir
acid
inhibitori
activ
acid
b
compar
zanamivir
influenza
b
sialidas
shown
scheme
inset
compound
highli
select
influenza
sialidas
factor
influenza
sialidas
acid
time
less
activ
zanamivir
wherea
acid
time
less
activ
find
indic
presenc
basic
function
requir
high
potenc
also
reveal
posit
doubl
bond
contribut
critic
high
activ
influenza
sialidas
author
explor
substitu
effect
well
potenti
synthes
compound
racem
form
prepar
nitrocyclohexen
da
cycloaddit
nitroolefin
dien
product
obtain
good
yield
submit
sequenc
wellestablish
chemic
convers
get
final
acid
b
excel
yield
scheme
inhibitori
activ
acid
b
influenza
b
sialidas
comparison
shown
scheme
compound
show
appreci
activ
compar
time
less
activ
influenza
sialidas
time
less
activ
influenza
b
sialidas
result
indic
amino
group
contribut
obligatori
high
potenc
although
import
bind
sialidas
poor
activ
acid
demonstr
inadequaci
synarrang
pentoxi
acetylamino
group
relev
relationship
sar
inform
futureplan
synthes
potenti
activ
analog
synthet
point
view
excel
endostereoselect
realiz
da
reaction
attribut
presenc
oacetyl
substitu
conclus
sialidas
inhibitori
properti
acid
b
provid
new
insight
sar
antiinfluenza
agent
relev
contrast
influenza
pandem
worldwid
concern
told
pandem
attribut
mutat
influenza
viru
protein
allow
viru
evad
human
immun
system
result
today
extens
global
transport
local
influenza
epidem
restrict
specif
area
high
mutat
frequenc
influenza
viru
effect
antiinfluenza
drug
target
fundament
molecular
process
essenti
specif
life
cycl
viru
principl
base
hypothesi
structur
fundament
protein
conserv
even
mutant
virus
na
belong
viru
protein
influenza
virion
bud
infect
cell
bind
termin
sialic
acid
residu
host
cell
surfac
glycoprotein
hemagglutinin
ha
fig
na
hydrolyt
cleav
glycosid
bond
sialic
acid
releas
viru
host
cell
surfac
process
liber
bud
virion
infect
cell
essenti
spread
infect
expect
activ
site
na
highli
conserv
across
influenza
b
viru
strain
therefor
na
inhibitor
prime
candid
broad
spectrum
antiinfluenza
drug
bind
studi
provid
molecularlevel
structur
inform
design
na
inhibitor
sever
research
group
academia
pharmaceut
industri
investig
topic
propos
differ
synthet
approach
potenti
activ
molecul
two
antiinfluenza
drug
zanamivir
glaxosmithklein
relenza
oseltamivir
phosphat
gilead
tamiflu
market
roch
inhibit
na
strongli
bind
activ
site
ic
valu
drug
nanomolar
rang
oseltamivir
phosphat
oral
activ
prodrug
activ
correspond
carboxyl
acid
form
wherea
zanamivir
low
bioavail
administ
inhal
drug
consid
effect
treat
influenza
although
molecul
rel
small
develop
practic
synthesi
provid
quantiti
requir
worldwid
highli
challeng
literaturepropos
synthet
strategi
oseltamivir
phosphat
base
da
strategi
roch
purpos
process
chemistri
provid
target
compound
larg
scale
ton
scale
effici
possibl
without
use
toxic
hazard
reagent
success
da
rout
direct
shown
scheme
synthesi
start
racem
da
reaction
furan
ethyl
acryl
reaction
proceed
presenc
equiv
zncl
afford
thermodynam
stabl
major
product
ratio
enzymat
resolut
allow
access
desir
r
isom
ee
convers
yield
compound
convert
endo
aziridin
treatment
diphenylphosphoryl
azid
cycloaddit
transesterif
phosphat
moieti
aziridineopen
compound
obtain
submit
hydrolysi
phosphoryl
amid
hydrochlorid
format
give
latter
convert
aziridin
format
introduct
amino
function
scheme
corey
et
al
report
concis
azidefre
synthesi
start
catalyz
enantioselect
da
reaction
develop
group
scheme
da
reaction
butadien
trifluoroethyl
acryl
proceed
room
temperatur
seal
tube
without
solvent
presenc
mol
triflimideactiv
oxazaborolidin
catalyst
give
cyclohexen
deriv
yield
ee
excel
enantioselect
explain
transit
state
model
butadien
approach
activ
dienophil
refac
opposit
shield
phenyl
group
catalyst
chiral
ligand
recov
effici
ammonolysi
follow
convers
nbocimid
oxalyl
chlorid
tbuoh
allow
success
bromolactam
perform
presenc
liotbu
nb
afford
elimin
hbr
diazabicycloundecen
dbu
allyl
bromin
follow
ethanolysi
basic
condit
produc
dienyl
ester
regioand
stereoselect
bromoamid
doubl
bond
achiev
origin
develop
method
use
nbromoacetamid
presenc
catalyt
amount
snbr
activ
br
donor
acetonitril
solvent
reaction
proceed
bromonium
ion
format
attract
interact
carbonyl
oxygen
boc
group
br
give
convers
oseltamivir
phosphat
straightforward
treatment
tetrabutylammonium
hexamethyldisilazid
produc
aziridin
intermedi
threememb
ringopen
accomplish
lewi
acidcatalyz
cu
reaction
cleavag
boc
group
conduct
h
po
give
besid
describ
chemic
transform
clearli
seen
pivot
step
corey
synthesi
catalyt
enantioselect
da
reaction
afford
enantiomer
enrich
start
compound
shibasaki
kanai
thirdgener
synthesi
start
da
reaction
trimethylsilan
fumaroyl
chlorid
run
room
temperatur
h
complet
tmsn
pyridin
dmap
ad
mixtur
correspond
acylazid
form
quench
reaction
hcl
desilyl
took
place
compound
obtain
yield
although
da
reaction
afford
endoexo
mixtur
diastereom
undesir
exo
isom
select
decompos
acid
cleavag
trimethylsilyl
tm
ether
curtiu
rearrang
conduct
heat
tbuoh
solut
acylazid
reflux
process
two
nitrogen
atom
differenti
afford
select
hydrolysi
cyclic
carbon
lioh
subsequ
nacetyl
produc
oxid
enon
modifi
moffat
condit
isobutyr
anhydrid
scheme
use
steric
bulki
anhydrid
step
essenti
order
avoid
oacyl
stage
enantiom
separ
chiral
hplc
nimedi
conjug
addit
tmscn
follow
elimin
hbr
stereoselect
reduct
lial
follow
bromolacton
produc
yield
moder
yield
attribut
asymmetr
da
reaction
easili
purifi
aqueou
acidbas
partit
crystal
chemic
enantiomer
pure
obtain
without
column
chromatographi
excel
enantioselect
da
reaction
explain
model
origin
propos
macmillan
dien
would
approach
activ
dienophil
side
opposit
bulki
benzyl
group
locat
catalyst
cbz
group
exchang
boc
group
oxid
catalyt
amount
ruo
nh
stoichiometr
amount
naio
afford
imid
intermedi
ruo
nh
recov
reus
quench
reaction
iproh
filtrat
ammonolysi
lacton
follow
omesyl
produc
amid
subject
hofmann
rearrang
presenc
phi
oac
allyl
alcohol
give
allyl
carbam
treatment
naoet
afford
aziridin
ethanolysi
imid
aziridin
elimin
hbr
onepot
fashion
aziridineopen
reaction
cleavag
boc
group
trifluoroacet
acid
tfa
nacetyl
deprotect
amin
phosphat
salt
format
produc
although
yield
catalyt
asymmetr
da
reaction
requir
improv
fukuyama
synthesi
within
practic
rang
thank
follow
point
start
materi
inexpens
pyridin
number
column
purif
minim
safe
common
reagent
use
synthesi
although
oseltamivir
rel
small
molecul
develop
practic
synthesi
satisfi
worldwid
demand
environment
friendli
safe
way
quit
challeng
roch
current
process
synthesi
reli
natur
occur
shikim
acid
start
materi
doubt
howev
artifici
asymmetr
catalyst
provid
potenti
straightforward
start
materi
synthet
rout
develop
three
academ
group
corey
shibasaki
kanai
fukuyama
group
support
viewpoint
new
synthet
methodolog
allow
chemist
design
conceptu
new
strategi
sens
improv
synthet
effici
intim
relat
progress
synthet
methodolog
anoth
import
research
vector
identifi
molecul
improv
pharmacolog
effect
like
drug
oseltamivir
phosphat
perfect
emerg
oseltamivirresist
influenza
viru
possibl
side
effect
human
nervou
system
two
major
concern
relat
oseltamivir
flexibl
synthet
rout
allow
synthesi
analog
order
address
problem
henc
organ
synthesi
activ
contribut
answer
biolog
question
safe
effect
vaccin
avail
protect
possibl
pandem
flu
na
inhibitor
therapi
oral
bioavail
good
toler
roch
tamiflu
recommend
best
choic
therapeut
prophylaxi
influenza
spread
avian
viru
make
situat
tamiflu
suppli
demand
increasingli
seriou
ration
optim
current
manufactur
process
base
increas
suppli
shikim
quinic
acid
improv
isol
ferment
synthesi
hand
new
synthet
rout
involv
complex
natur
product
precursor
rather
cheap
wide
avail
commod
chemic
also
develop
academ
chemist
report
signific
result
experiment
studi
discoveri
new
function
molecul
extrem
import
task
synthet
chemist
regard
contrast
influenza
virus
interest
shortstep
synthesi
model
core
structur
associ
halenaquinon
relat
natur
compound
report
prepar
furanfus
tetracycl
compound
notabl
antivir
activ
concis
synthes
basi
oquinodimethan
chemistri
scheme
pivot
step
repres
intramolecular
da
reaction
quinodimethan
intermedi
furan
moieti
act
dienophil
sever
acut
respiratori
syndrom
sar
congen
investig
aim
discoveri
new
candid
antivir
drug
preliminari
studi
antivir
activ
survey
use
assay
method
ha
titer
sever
deriv
potent
antivir
activ
lead
compound
obtain
especi
triisopropylsilyl
tip
deriv
reveal
lowest
minimum
inhibitori
concentr
mic
valu
good
therapeut
index
result
prompt
author
investig
possibl
reveal
dihydrofuranfus
compound
new
class
antiinfluenza
agent
possess
novel
structur
characterist
inhibitori
activ
compound
includ
investig
viral
growth
canin
kidney
mdck
cell
use
influenza
subtyp
viru
strain
mm
drug
concentr
result
show
sever
compound
inhibit
viru
growth
could
potenti
new
antiinfluenza
agent
particular
modifi
structur
exhibit
potent
activ
suppress
viru
prolifer
ca
control
summari
influenza
longstand
health
problem
develop
na
inhibitor
promis
new
hope
viru
treatment
tamiflu
phosphat
salt
oseltamivir
oral
avail
na
inhibitor
design
cyclohexen
scaffold
mimic
structur
oxoniumlik
intermedi
enzymat
cleavag
termin
sialosid
cell
receptor
scheme
mani
new
synthet
procedur
without
use
shikim
acid
explor
current
industri
manufactur
may
shortag
shikim
acid
global
suppli
influenza
pandem
shikimateindepend
synthes
sever
differ
approach
util
construct
multipl
substitut
cyclohexen
ring
use
exist
sixmemb
ring
construct
da
reaction
construct
intramolecular
aldol
dieckmann
wittig
reaction
construct
tandem
reaction
construct
olefin
metathesi
construct
claisen
rearrang
phosphon
group
gener
use
bioisoster
carboxyl
drug
design
synthes
tamiphosphor
zanaphosphor
influenza
virus
includ
oseltamivirresist
strain
accord
na
inhibit
cellbas
assay
mice
experi
first
time
phosphon
monoalkyl
ester
prove
real
activ
drug
prodrug
parent
phosphon
acid
review
cover
design
synthesi
biolog
activ
phosphon
compound
effect
antiinfluenza
agent
mechanist
point
view
synthet
approach
report
find
use
applic
synthes
fact
oquinodimethan
intramolecular
cycloaddit
appli
total
synthesi
estran
type
steroid
exampl
first
asymmetr
total
synthesi
chenodeoxychol
acid
achiev
via
intramolecular
cycloaddit
oquinodimethan
key
step
scheme
flexibl
effici
rout
aromat
nonaromat
steroid
plan
basi
type
reaction
sequenc
rout
transbenzoperhydroindan
set
key
compound
prepar
either
atrien
nonaromat
steroid
respect
easi
manipul
benzen
ring
turn
could
access
intramolecular
cycloaddit
oquinodimethan
gener
situ
thermolysi
benzocyclobuten
scheme
typic
exampl
applic
methodolog
synthesi
shown
scheme
synthet
strategi
character
onestep
creation
b
c
e
ring
stereoselect
manner
via
intramolecular
cycloaddit
reaction
oquinodimethan
are
format
follow
function
posit
result
show
investig
reaction
proceed
high
stereoselect
lead
prefer
format
isom
thu
seem
possibl
high
stereoselect
might
reflect
sever
steric
interact
present
endo
transit
state
exo
transit
state
comparison
exo
transit
state
thu
could
obtain
inform
stereochem
outcom
da
cycloaddit
reaction
olefin
oquinodimethan
asymmetr
substitut
tertiari
chiral
center
facil
thermal
allow
conrotatori
ring
open
cyclobuten
known
depend
electron
natur
substitu
cyclobuten
ring
cours
studi
substitu
effect
reaction
except
facil
ring
open
reaction
cyclobuten
observ
arylsulfinyl
arylsulfonyl
diphenylphosphinyl
substitu
locat
cyclobuten
structur
reaction
carri
triisopropylsilyl
thf
c
min
use
nbutyllithium
base
found
proceed
moder
high
yield
use
small
ring
compound
synthes
variou
pharmacolog
import
compound
novel
reaction
mode
specif
ring
system
larg
demonstr
find
may
serv
mean
develop
new
reaction
synthet
methodolog
applic
da
cycloaddit
reaction
synthesi
antivir
compound
also
find
hetero
version
process
wide
panorama
valuabl
reaction
focus
reader
attent
specif
case
abl
open
wider
rang
opportun
access
target
compound
known
time
aminosugar
deriv
inhibit
glycoprotein
process
potenti
activ
hiv
natur
occur
aminodeoxysugar
deriv
either
piperidin
pyrrolidin
pyrrolizin
octahydroindolizin
depriv
anomer
oh
group
compound
deriv
amino
erythros
fall
within
pyrrolidin
group
synthesi
compound
reli
upon
hda
cycloaddit
reaction
nitrosocarbonyl
intermedi
tschamber
et
al
show
nitrosodienophil
react
face
select
convex
type
azetidinodiazepin
give
direct
invers
cycloadduct
type
high
yield
scheme
result
agre
previous
describ
high
faceselect
da
process
acylnitrosodienophil
ie
benzyloxycarbonylnitroso
dienophil
prepar
situ
correspond
hydroxam
acid
accord
known
procedur
react
dien
compon
afford
primari
amino
group
introduc
azid
elimin
acetyl
catalyt
osmyl
presenc
cooxid
nmethylmorpholin
noxid
nmo
gave
excel
yield
expect
ci
diol
type
transform
correspond
acetonid
deriv
ie
onepot
hydrogenolys
h
pdc
singl
bond
benzyloxycarbonyl
moieti
trigger
molecular
rearrang
led
ultim
pyrrolidin
deriv
b
format
result
mechanist
straightforward
multistep
sequenc
hydrogenolysi
bond
follow
decarboxyl
hemiamin
function
break
lead
aldehyd
condens
primari
nh
c
amin
ensu
pyrrolin
hydrogen
pdc
give
pyrrolidin
multistep
mechan
akin
one
observ
catalyt
hydrogenolysi
trihydroxytetrahydroxazin
led
also
dihydroxypyrrolidin
compound
test
antihiv
activ
compound
evalu
two
separ
experi
duplic
primari
screen
hiv
strain
gb
jm
cell
assay
activ
measur
syncytium
format
cytotox
mtt
assay
use
castanospermin
refer
compound
assay
hydrochlorid
show
antivir
activ
less
pronounc
castanospermin
uloson
acid
group
natur
occur
carbohydr
involv
mani
biolog
import
process
attract
consider
attent
last
year
seven
carbonatom
analog
seri
acid
dah
form
plant
stereoselect
condens
phosphoenolpyruv
derythros
mediat
dahp
synthas
shown
dah
key
intermedi
biosynthesi
aromat
amino
acid
glucos
shikim
pathway
therefor
surpris
compound
type
becom
target
mani
synthet
endeavor
wu
et
al
propos
effici
methodolog
synthesi
ethyl
ester
acid
acid
use
chiral
catalyst
ii
complex
hda
reaction
led
signific
improv
yield
select
key
step
synthesi
involv
effici
elabor
silyl
enol
ether
prepar
dglyceraldehyd
acetonid
scheme
synthesi
base
hda
cycloaddit
reaction
dien
ethyl
glyoxyl
presenc
ii
complex
afford
yield
hydroxyl
catalyt
amount
oso
mol
equiv
nmo
room
temperatur
h
provid
mixtur
yield
diastereoselect
howev
unaccept
low
separ
product
difficult
asymmetr
dihydroxyl
conduct
treatment
c
room
temperatur
afford
convers
start
materi
even
prolong
reaction
scheme
synthet
strategi
zanamivir
relat
compound
time
better
convers
later
achiev
employ
larger
amount
k
oso
oh
mol
singl
diastereoisom
could
obtain
yield
excel
diastereoselect
attribut
match
interact
substrat
chiral
chiral
ligand
reduct
keton
nabh
c
ethanol
provid
transdiol
yield
hydroxyl
group
protect
acet
follow
select
hydrolysi
termin
oisopropyliden
acet
oxid
cleavag
expos
glycol
period
acid
follow
reduct
result
termin
aldehyd
nabh
gave
compound
two
step
isol
yield
final
deprotect
k
co
etoh
afford
ethyl
treatment
hinder
lithium
tritbutoxi
aluminum
hydrid
thf
c
h
gave
mixtur
cisand
transisom
yield
select
yield
improv
ci
tran
yield
reaction
temperatur
lower
c
protect
isopropyliden
acet
yield
oxid
isopropyliden
remov
reaction
dowex
h
ethanolwat
c
afford
ethyl
quantit
ester
use
precursor
simpl
analog
antiinfluenza
agent
ie
zanamivir
acid
known
viral
na
sialidas
inhibitor
follow
intranas
administr
ferret
least
time
effect
ribavirin
amantadin
influenza
b
virus
retain
activ
even
treatment
delay
h
postinfect
effect
serum
antibodi
respons
infect
method
stereoselect
introduct
hydroxi
group
illustr
work
may
also
applic
synthes
member
seri
compound
applic
strategi
synthes
kdn
analog
investig
basi
excel
hda
strategi
anoth
promis
na
inhibitor
known
current
evalu
clinic
trial
scheme
compound
demonstr
notabl
select
potenc
na
wide
rang
influenza
b
virus
emphas
rel
posit
interact
function
group
essenti
na
inhibitori
potenc
rather
absolut
posit
central
ring
stereoselect
synthesi
tetrasubstitut
cyclopentan
describ
miller
et
al
emphas
util
acylnitroso
cycloaddit
chemistri
start
materi
synthes
na
inhibitor
racem
oxazanorbornen
deriv
protect
boc
group
synthes
scheme
reduct
bond
cleavag
use
mo
co
nabh
gave
allyl
alcohol
convert
ethyl
carbon
treatment
ethyl
chloroform
ethyl
carbon
moieti
replac
nitromethyl
group
reaction
meno
catalyt
amount
pd
furnish
primari
nitro
compound
transform
carboxyl
acid
employ
mixtur
nano
acoh
dimethylformamid
dmf
follow
treatment
catalyt
amount
tm
cl
meoh
give
correspond
methyl
ester
subsequ
elabor
describ
later
carri
racem
either
enantiom
could
prepar
start
correspond
antipod
avail
enzymat
resolut
author
util
nitril
oxid
dipolar
cycloaddit
incorpor
key
addit
framework
compon
function
rather
bulki
bocprotect
amin
methyl
ester
group
anticip
induc
select
reaction
nitril
oxid
opposit
face
howev
regiochemistri
reaction
less
predict
preced
indic
would
proceed
desir
nitril
oxid
deriv
correspond
oxim
situ
gener
known
nitril
oxid
bear
wide
rang
substitu
capabl
particip
dipolar
cycloaddit
reaction
scheme
precursor
dipolar
cycloaddit
compound
oxim
contain
diethyl
unit
prepar
commerci
avail
aldehyd
hydroxylamin
yield
reaction
dipolarophil
oxim
transform
correspond
nitril
oxid
dipol
situ
presenc
naocl
et
n
induc
dipolar
cycloaddit
provid
bicycl
isoxazolin
confirm
xray
crystallograph
analysi
desir
isom
isol
product
despit
possibl
gener
unwant
stereoand
regioisom
isoxazolin
ring
subject
hydrogenolysi
meoh
contain
pto
equival
amount
hcl
psi
subsequ
acetyl
furnish
compound
precursor
final
product
upon
remov
boc
protect
group
compound
convert
correspond
protect
guanidino
deriv
treatment
tboc
presenc
hgcl
subsequ
basic
hydrolysi
n
naoh
afford
correspond
acid
yield
cleavag
boc
protect
group
use
tfa
ch
cl
presenc
et
sih
tbutyl
cation
scaveng
furnish
desir
final
product
yield
move
sugar
pseudosugar
alkaloid
ere
decarboxyl
camptothecin
analog
nothapodytin
b
isol
nothapodyt
foetida
nothapodytin
b
mappicin
keton
oxid
deriv
natur
alkaloid
mappicin
show
signific
cytotox
human
kb
cell
line
fig
sinc
nothapodytin
b
mappicin
keton
identifi
antivir
agent
select
activ
herp
simplex
viru
hsv
famili
alkaloid
receiv
consider
attent
organ
chemist
limit
suppli
mappicin
keton
made
necessari
develop
novel
synthet
methodolog
prepar
exampl
offer
novel
synthet
approach
mappicin
employ
intramolecular
hda
reaction
key
step
propos
synthesi
toyota
komori
ihara
reli
upon
chemistri
although
littl
known
practic
applic
hda
reaction
deriv
construct
polycycl
natur
alkaloid
start
compound
synthesi
mappicin
quinolineazid
scheme
amid
format
reaction
carri
literatur
report
procedur
reduct
wet
triphenylphosphin
follow
condens
fumar
acid
monoethyl
ester
presenc
bop
hunig
base
gave
unsatur
amid
overal
yield
intramolecular
hda
reaction
led
cycloadduct
treat
aqueou
hydrogen
bromid
provid
ethyl
ester
yield
singl
step
electronwithdraw
substitu
group
ethyl
ester
imped
cycloaddit
contrari
promot
autoxid
correspond
cycloadduct
final
ethyl
ester
subject
transesterif
reaction
methanol
presenc
concentr
h
afford
product
compound
alreadi
transform
nothapodytin
b
mappicin
kametani
et
al
reduct
ester
moieti
nearli
year
american
research
group
propos
altern
rout
target
key
requir
use
lumo
dien
control
hda
reaction
treatment
room
temperatur
h
benzen
led
format
sensit
cycloadduct
notabl
deliber
incorpor
noncomplementari
electronwithdraw
substitu
result
hda
cycloaddit
proceed
c
presum
lower
dien
lumo
without
alter
inher
cycloaddit
regioselect
scheme
due
expect
sensit
hda
adduct
hydrolysi
subsequ
aromat
crude
adduct
tbuok
thf
c
min
provid
methoxypyridin
deriv
good
yield
without
intermedi
isol
presum
aromat
proce
initi
basecatalyz
elimin
methanesulfin
acid
facilit
substitut
follow
elimin
methanol
addit
etmgbr
presenc
tertiari
amin
etmgbr
et
n
toluen
c
h
proceed
cleanli
give
correspond
ethyl
keton
without
competit
tertiari
alcohol
format
virtu
tertiari
aminepromot
keton
enol
final
step
requir
cycliz
form
c
ring
accomplish
one
oper
treatment
satur
solut
hbr
g
cf
ch
oh
c
h
follow
addit
k
co
c
h
provid
nothepodytin
b
mappicin
keton
directli
without
workup
isol
intermedi
approach
work
beauti
give
keton
overal
yield
final
product
prove
ident
respect
properti
report
authent
materi
reduct
nothepodytin
b
mappicin
keton
nabh
first
describ
kametani
later
kingsburi
comin
provid
mappicin
addit
reduct
nothepodytin
b
mappicin
keton
binalh
provid
mappicin
ee
exhibit
cd
spectrum
ident
describ
natur
occur
materi
confirm
origin
absolut
configur
assign
cytotox
evalu
cell
line
form
weakli
cytotox
ic
respect
hiv
proteas
inhibitor
pi
continu
essenti
compon
arsen
fight
hiv
infect
aid
viral
enzym
unusu
abil
cleav
peptid
bond
phenylalanin
prolin
inhibitor
incorpor
hydroxyethylamin
transitionst
mimet
phepro
saquinavir
inset
scheme
potent
select
inhibitor
hiv
proteas
report
synthesi
allow
readi
substitut
carbocycl
ring
region
could
potenti
lead
enhanc
potenc
better
pharmacokinet
properti
inhibitor
develop
chiral
da
rout
allow
readi
synthesi
rang
substitut
carbocycl
mimet
scissil
phepro
dienophil
react
trimethylsilyloxi
thermal
condit
react
smoothli
lewi
acid
catalysi
give
workup
mixtur
diastereomer
transketon
yield
requir
isom
easili
separ
scheme
oxazolidinon
thu
convert
acid
treatment
lithium
hydroxidehydrogen
peroxid
thenc
requir
tertbutylamid
via
nhydroxysuccinimid
ester
equatori
axial
alcohol
could
obtain
respect
use
lselectrid
excel
yield
select
also
could
readili
convert
rang
ether
treatment
sodium
hydrid
dmf
c
correspond
alkyl
halid
axial
alcohol
could
also
convert
satur
carbocycl
transform
mesyl
elimin
reduct
follow
elabor
carbocycl
ring
boc
acetonid
protect
group
easili
remov
use
dichloromethanetfa
contain
drop
water
give
amin
suitabl
elabor
inhibitor
hiv
proteas
virantmycin
scheme
unusu
chlorin
member
larg
class
tetrahydroquinolin
alkaloid
isol
strain
streptomyc
nitrosporeu
omura
et
al
found
potent
dna
rna
viru
inhibitor
well
antifung
agent
sever
total
synthes
racem
virantmycin
natur
virantmycin
unnatur
antipod
propos
stress
import
promis
pharmacolog
profil
substanc
variou
synthet
approach
toward
construct
tetrahydroquinolin
ring
system
avail
includ
insert
ring
expans
ring
contract
reaction
howev
one
versatil
converg
strategi
construct
tetrahydroquinolin
alkaloid
hda
reaction
oazaxylylen
form
suitabl
benzyl
halid
precursor
suitabl
dienophil
one
key
fragment
synthet
rout
toward
virantmycin
arylthiocarbam
scheme
substanc
known
year
synthet
methodolog
reliabl
highyield
format
scarc
classic
method
develop
paal
laudenheim
heat
alcohol
alcohol
presenc
triphenylphosphan
staudingertyp
reaction
lead
iminophosphoran
intermedi
react
carbon
disulfid
seal
vial
elev
temperatur
yield
cycliz
product
yield
allyl
alcohol
allow
react
appeltyp
reaction
cyclic
thiocarbam
use
standard
condit
reaction
proceed
smoothli
purif
product
prove
cumbersom
reaction
byproduct
triphenylphosphan
sulfid
easili
remov
column
chromatographi
exposur
dissolv
crude
reaction
product
dichlromethan
dcm
treatment
trifluoroacet
anhydrid
synthes
desir
carbam
isol
yield
due
complet
synthesi
advanc
carbam
intermedi
stage
set
key
cycloaddit
dri
cesium
carbon
sever
hour
torr
c
ad
solut
dcm
stir
room
temperatur
smoothli
provid
tricyclu
yield
complet
synthesi
could
achiev
aromat
iodin
use
iodin
monochlorid
dcm
provid
desir
compound
singl
regioisom
yield
synthesi
advanc
precursor
complet
four
consecut
step
start
overal
yield
remain
step
total
synthesi
toward
virantmycin
alreadi
perform
identif
biolog
activ
organ
compound
utmost
import
basic
research
drug
develop
besid
classic
approach
identifi
compound
vitro
screen
ie
bind
isol
protein
highcont
cellbas
screen
proven
power
complementari
approach
propos
employ
framework
natur
product
class
evolutionari
select
biolog
prevalid
start
point
structur
space
compound
collect
develop
repres
interest
research
rout
develop
treelik
classif
natur
product
framework
identifi
natur
biologyori
synthesi
compound
collect
deriv
natur
product
framework
provid
promis
strategi
search
new
biolog
activ
agent
effici
carri
polymerbound
substrat
allow
rapid
diversif
without
intermedi
purif
step
natur
productderiv
inspir
compound
collect
synthes
solid
support
number
case
howev
order
meet
stereochem
demand
natur
product
framework
use
enantioselect
transform
solid
phase
present
highli
attract
though
rare
address
approach
scheme
report
enantioselect
solidphas
synthesi
natur
productinspir
collect
investig
cellbas
screen
monitor
cell
cycl
progress
viral
entri
cell
motif
belong
frequent
occur
scaffold
natur
characterist
underli
structur
element
antiprolif
agent
immunosuppress
inhibitor
differ
enzym
particular
protein
phosphatas
develop
asymmetr
solidphas
synthesi
enantioselect
oxa
hda
reaction
aldehyd
electronrich
immobil
polymer
carrier
key
stereodifferenti
transform
synthes
solid
support
start
wang
bromoresin
subject
enantioselect
cycloaddit
ethyl
glyoxyl
reactiv
heterodienophil
scheme
enantioselect
hda
reaction
ethyl
glyoxyl
proceed
ee
presenc
mol
ti
r
binol
complex
absolut
rel
configur
cycloadduct
determin
releas
lacton
resin
comparison
specif
rotat
characterist
nuclear
magnet
reson
nmr
data
correspond
valu
report
literatur
simpl
transform
ester
could
elabor
resinbound
final
compound
type
cleavag
resin
compound
test
biolog
activ
synthes
compound
collect
subject
aforement
cellbas
screen
monitor
influenc
cell
cycl
progress
screen
cell
african
green
monkey
cultur
plate
treat
h
synthes
compound
cell
line
chosen
due
proven
advantag
assess
influenc
chemic
compound
cell
cycl
treat
cell
fix
formaldehyd
stain
chromatin
actinand
microtubul
cytoskeleton
microscop
analysi
reveal
sever
investig
compound
influenc
microtubul
cytoskeleton
divid
andor
nondivid
cell
previou
paragraph
saw
tamiflu
oseltamivir
phosphat
recogn
key
weapon
combat
new
type
influenza
import
demand
increas
tamiflu
first
develop
gilead
scienc
synthes
market
roch
product
perform
start
shikim
acid
natur
product
develop
new
synthesi
nonnatur
readili
avail
chemic
feedstock
requir
synthesi
tamiflu
investig
mani
group
world
total
synthesi
accomplish
corey
shibasaki
other
construct
polyfunction
cyclohexen
unit
hda
approach
pyrrol
acetylen
investig
japanes
research
group
synthesi
start
hda
reaction
nbocpyrrol
scheme
solut
bromoacetylen
carboxyl
nbocpyrrol
heat
c
h
da
adduct
isol
yield
treatment
mcpba
gave
yield
oxid
took
place
stereoselect
manner
prepar
singl
isom
use
oxon
convers
result
format
mixtur
isom
author
succeed
improv
yield
repeat
reaction
procedur
twice
reduct
basic
hydrolysi
yield
correspond
carboxyl
acid
open
epoxid
give
tricycl
lacton
alcohol
yield
one
step
synthet
step
requir
convert
lacton
encoepoxid
obtain
yield
convers
cyclohexeneepoxid
greatli
enhanc
hexamethylphosphoramid
hmpa
use
cosolv
reaction
lithium
diisopropylamid
lda
thf
c
yield
yield
presenc
equival
hmpa
final
stage
synthesi
perform
follow
way
scheme
instal
group
achiev
treatment
presenc
bf
oet
obtain
compound
yield
epimer
hydroxyl
group
carri
oxidationreduct
pathway
thu
convers
correspond
keton
achiev
treatment
periodinan
dmp
reduct
nabh
smoothli
gave
yield
diastereoselect
convers
tamiflu
alreadi
report
thu
conclud
formal
synthesi
tamiflu
readili
avail
organ
feedstock
overal
yield
step
proceed
suffici
stereoselect
manner
octan
isoquinuclidin
found
wide
natur
product
ibogatyp
indol
alkaloid
vari
interest
biolog
properti
vinca
alkaloid
vinblastin
vincristin
possess
isoquinuclidin
aspidosperma
portion
indic
ibogain
reduc
crave
alcohol
drug
mean
abil
boost
level
growth
factor
known
glial
cell
neurotroph
factor
addit
also
shown
isoquinuclidin
use
synthet
intermedi
synthesi
oseltamivir
phosphat
furthermor
isoquinuclidin
also
valuabl
intermedi
synthesi
alkaloid
medicin
chemistri
therefor
meaning
establish
effect
asymmetr
synthet
methodolog
chiral
isoquinuclidin
wellestablish
rout
chiral
ring
system
asymmetr
hda
reaction
dienophil
howev
exampl
employ
organomet
catalyst
organocatalyst
report
despit
obviou
advantag
catalyt
enantioselect
version
use
organocatalyst
best
knowledg
one
exampl
employ
macmillan
catalyst
report
organocatalyt
asymmetr
version
reaction
use
key
reaction
effici
practic
total
synthesi
tamiflu
fukuyama
et
al
effect
acrolein
deriv
investig
use
superior
catalyst
scheme
presenc
azadien
reaction
carri
c
presenc
mol
give
da
adduct
yield
ee
first
exampl
enantioselect
da
reaction
substitut
dienophil
use
organocatalyst
reduct
nabh
led
alcohol
final
convert
desir
target
alreadi
seen
sialic
acid
close
relat
carboxyl
sugar
widespread
mammalian
glycoprotein
glycolipid
typic
found
outermost
end
glycan
chain
kind
cell
involv
varieti
physiochem
patholog
process
class
sugar
structur
modulatori
role
serv
compon
bind
site
variou
pathogen
toxin
addit
anoth
import
function
play
decor
microbi
pathogen
allow
evad
host
immun
influenza
viru
subdivid
three
serolog
distinct
typesa
b
call
recogn
sialic
acid
deriv
function
receptor
sialidas
influenza
viru
surfac
enzym
recogn
nacetylneuramin
acid
moieti
typic
associ
termin
saccharid
unit
mammalian
glycoconjug
search
new
sialidaseinhibitor
antiinfluenza
drug
synthesi
new
class
exo
enitol
obtain
use
electronrich
dienophil
chemo
regio
stereoselect
hda
reaction
dioxothion
electronpoor
dien
form
diasteromer
pure
deriv
structur
attract
develop
new
inhibitor
sialidas
develop
italian
greek
research
group
methyl
ester
convert
room
temperatur
tertbutyldimethylsilyl
triflat
tbdmsotf
afford
tri
silyl
deriv
yield
scheme
direct
reduct
treatment
sodium
borohydrid
isopropanol
subsequ
oxid
lacton
realiz
sodium
period
methanolwat
solvent
yield
calcul
two
step
desir
exo
enitol
final
obtain
reaction
tebb
reagent
pyridin
compound
isol
yield
singl
diasteroisom
heterodien
select
react
dienophil
obtain
treat
commerci
avail
phthalimidosolfenyl
chlorid
phtnscl
pyridin
report
condit
dioxothion
form
mild
condit
phtalimido
deriv
trap
situ
exo
enitol
invers
electrondemand
da
reaction
cycloaddit
reaction
total
chemoand
regioselect
cycloadduct
obtain
singl
diasteroisom
ethyl
ester
isol
pure
anom
hydrolyz
obtain
put
bind
mode
newli
synthes
compound
within
na
activ
site
dock
calcul
conduct
compound
deriv
ethyl
ester
precursor
consid
studi
sinc
expect
readili
hydrolyz
endogen
esteras
vivo
crystallograph
structur
complex
sialic
acid
influenza
viru
sialidas
employ
order
make
direct
comparison
interact
activ
site
residu
fig
two
model
compound
prepar
pyranos
ring
either
chair
boat
configur
bound
conform
retain
intermolecular
interact
na
activ
site
residu
fig
display
minim
differ
glycerol
moieti
estim
mean
free
energi
bind
kcalmol
correspond
inhibit
constant
analysi
dock
result
obtain
compound
reveal
high
number
distinct
conform
cluster
mani
adopt
complet
differ
bind
mode
comparison
consequ
hydrogenbond
interact
display
activ
site
residu
na
lost
hand
dock
boat
configur
bound
exhibit
two
conform
cluster
approxim
bind
mode
compound
highest
energi
conform
top
rank
cluster
mean
free
energi
bind
kcalmol
shown
fig
bind
mode
carboxyl
group
slightli
shift
respect
sialic
acid
thu
maintain
hydrogenbond
network
howev
proper
accommod
oxathiin
moieti
insid
activ
site
pyranos
ring
rotat
shift
toward
residu
result
loss
hydrophob
contact
compound
predict
interact
residu
display
complex
albeit
lower
affin
mainli
due
loss
kcalmol
electrostat
energi
term
compound
pfluorophenyl
substitu
give
rise
larger
shift
oxathiin
ring
toward
thu
lose
contact
fig
bind
mode
pfluorophenyl
group
display
contact
protein
residu
addit
interact
present
exhibit
van
der
waal
contact
glycerol
sidechain
reason
compound
predict
bind
sialidas
even
lower
affin
mean
free
energi
bind
kcalmol
conclus
oxathiin
ring
spiroket
compound
might
displac
pyranos
ring
crystallograph
posit
display
sialic
acid
deriv
though
proper
function
spiroket
scaffold
could
compens
interact
key
amino
acid
residu
na
new
spiroket
scaffold
could
repres
novel
class
sialidas
inhibitor
deriv
constitut
import
seri
biolog
activ
compound
import
intermedi
modern
medicin
synthet
organ
chemistri
possess
synthet
multifunction
bioactiv
divers
pharmacolog
area
synthet
strategi
base
heterodien
hda
reaction
nevertheless
type
hda
reaction
rare
use
limit
number
dienophil
acryl
maleic
acid
deriv
hda
reaction
scheme
afford
azabicycl
compound
remark
subunit
alkaloid
natur
product
ibogain
dioscorin
coronaridin
among
isoquinuclidin
ring
system
emin
import
potenti
bioactiv
compound
pharmaceut
also
numer
natur
compound
terpen
alkaloid
drug
contain
pure
carbocycl
scaffold
particularli
deriv
sever
bridg
carbobicycl
compound
exocycl
imin
group
report
highli
activ
trypanosoma
b
rhodesiens
resist
strain
plasmodium
falciparum
sever
approach
azabicyclo
compound
known
literatur
reaction
enabl
conveni
direct
metalfre
rout
complex
bridg
carboand
heterobicycl
use
malononitril
aldehyd
strikingli
simpl
start
compound
never
investig
aldehyd
electrophil
simpl
start
materi
scheme
report
use
aldehyd
equiv
malononitril
equiv
presenc
imidazol
mol
load
synthet
attent
direct
artemisininderiv
aldehyd
substrat
sinc
semin
discoveri
artemisinin
natur
sesquiterpen
artemisia
annua
l
youyou
tu
nobel
prize
equiv
artemisininderiv
hybrid
b
synthes
overal
yield
ratio
hybrid
b
synthes
overal
yield
ratio
correspond
product
form
fig
report
complex
mechan
suggest
author
support
densiti
function
theori
dft
calcul
well
mass
spectrometri
ms
investig
allow
detect
synthet
intermedi
obtain
hybrid
investig
biolog
point
view
remark
hybrid
b
display
superior
potenc
human
cytomegaloviru
ec
respect
compar
parent
compound
artemisinin
ec
even
activ
clinic
use
antivir
agent
ganciclovir
thiazolidinonebas
molecul
attract
target
ration
design
druglik
compound
possess
antiinflammatori
antioxid
antitumor
choleret
diuret
activ
addit
known
inhibitor
phosphatas
hcv
proteas
antiapopt
protein
complex
bclxlbh
complex
ra
farnesyl
transferas
among
thiazolidinon
deriv
wide
interest
due
divers
biolog
activ
clinic
applic
previou
studi
thiopyrano
thiazol
report
potenti
antitripanosom
antioxid
anticanc
antiinflammatori
agent
seri
novel
thiopyrano
prepar
found
activ
antitumor
antivir
compound
synthesi
compound
base
upon
cycliz
acrolein
via
hda
reaction
synthesi
target
thiopyrano
thiazol
follow
gener
pathway
outlin
scheme
specif
compound
first
start
obtain
knoevenagel
condens
sever
aldehyd
presenc
edda
base
catalyst
reactiv
sulfur
atom
allow
use
highli
activ
heterodien
compon
hda
reaction
synthes
compound
evalu
antivir
activ
regard
viru
found
compound
show
excel
activ
ec
si
vca
elisa
test
possess
moder
activ
si
varicella
zoster
viru
si
viral
chlorin
polyethylen
cpe
test
design
synthesi
evalu
new
class
except
potent
pi
report
american
japanes
research
group
studi
structur
design
strategi
base
upon
promot
extens
interact
activ
site
proteas
author
examin
compar
xray
structur
variat
critic
activ
site
interact
numer
pi
bound
wildtyp
mutant
proteas
therefor
promis
inhibitor
design
strategi
would
maxim
activ
site
interact
particularli
promot
robust
network
hydrogenbond
interact
backbon
atom
wildtyp
proteas
depict
fig
design
model
combat
drug
resist
involv
design
ligand
would
form
robust
hydrogen
bond
polar
group
region
furthermor
synthet
plan
requir
fill
hydrophob
subsit
hydrophob
ligand
among
mani
possibl
class
transitionst
binder
incorpor
r
hydroxyethylamin
sulfonamid
isoster
perform
readili
vari
substitu
provid
nonpeptid
druglik
optic
puriti
alcohol
determin
ee
chiral
hplc
analysi
alcohol
convert
bicycl
acet
threestep
sequenc
obtain
yield
lactol
mixtur
treat
tfa
dcm
afford
remov
tb
group
tetrabutylammonium
fluorid
alcohol
yield
two
step
exoalcohol
convert
endoalcohol
oxid
follow
reduct
result
keton
nabh
meoh
yield
two
step
exoand
endoalcohol
convert
correspond
mix
activ
carbon
deriv
type
excel
yield
final
step
ligand
stand
coupl
activ
carbon
endoand
exo
crownlik
thf
type
presenc
diisopropylethylamin
furnish
inhibitor
good
yield
examin
preliminari
model
endo
crownlik
thf
contain
inhibitor
exo
crownlik
thfderiv
inhibitor
indic
acet
oxygen
endoderiv
suitabl
posit
form
hydrogen
bond
amid
nh
also
tricycl
scaffold
inhibitor
appear
fill
hydrophob
pocket
site
effect
inhibitor
inhibitor
contain
xray
crystal
structur
wild
type
proteas
cocrystal
inhibitor
refin
contain
proteas
dimer
inhibitor
bound
proteas
two
orient
relat
rotat
rel
occup
fig
inhibitor
bound
activ
site
caviti
form
seri
hydrogen
bond
interact
numer
weaker
ch
interact
main
chain
atom
proteas
major
conform
inhibitor
form
hydrogen
bond
interact
urethan
nh
carbonyl
oxygen
inhibitor
also
form
tetracoordin
watermedi
interact
connect
inhibitor
carbonyl
oxygen
sulfonamid
oxygen
amid
flap
furthermor
pmethoxi
group
sulfonamid
form
hydrogen
bond
amid
nh
well
side
chain
carboxyl
group
move
field
terpen
type
viru
vitro
rabbit
eye
synthet
approach
reli
upon
condens
cyclohexanon
deriv
presenc
lda
afford
convert
intermedi
critic
heck
cycliz
via
claisen
condens
wacker
oxid
dien
obtain
yield
lead
product
intramolecular
da
reaction
yield
step
convert
target
compound
wellknown
number
natur
product
contain
quinon
moieti
antibiot
mitomycin
c
anthracyclicn
show
remark
biolog
activ
toddacoumaquinon
uniqu
coumarinnaphtoquinon
dimer
isol
toddalia
asiatica
synthesi
plan
da
cycloaddit
dien
quinon
scheme
compound
test
antivir
activ
use
acyclovir
control
compound
show
weak
activ
viru
strain
sevenmemb
lacton
easili
isomer
cisfus
fivememb
lacton
desir
stereochem
featur
pd
catalyz
lacton
migrat
reaction
final
compound
obtain
step
racem
form
ascochlorin
antivir
antibiot
obtain
filter
cake
ferment
broth
ascochyta
vicia
libert
strong
inhibitori
effect
viral
growth
cultur
cell
compound
featur
three
stereogen
center
sesquiterpen
unit
system
aromat
unit
aldehyd
methyl
chlorid
two
hydroxi
substitu
due
high
biolog
activ
ascochlorin
famili
attract
attent
synthet
chemist
among
total
synthes
ascochlorin
report
literatur
exampl
asymmetr
da
reaction
follow
cuprat
juli
olefin
reaction
key
strategi
total
synthesi
biolog
activ
natur
compound
report
synthesi
sesquiterpen
unit
tigloylsultam
allow
react
give
desir
da
adduct
yield
de
chiral
auxiliari
easili
remov
treatment
cycloadduct
lioh
presenc
h
gave
cyclohexenecarboxyl
acid
yield
recov
sultam
auxiliari
yield
scheme
standard
iodolacton
methodolog
appli
crude
carboxyl
acid
reaction
yield
desir
iodolacton
yield
cleavag
lacton
unit
lialh
oxid
allyl
alcohol
mno
afford
desir
unsatur
keton
reduct
first
oxid
result
alcohol
swern
oxid
reaction
condit
cleanli
gave
aldehyd
juli
olefin
afford
desir
compound
precursor
effort
discov
novel
microbi
metabolit
led
isol
new
class
natur
product
call
pradimicin
benanomicin
pradimicin
b
c
shown
activ
variou
fungi
yeast
virus
uniqu
biolog
activ
class
compound
exhibit
ongo
need
antifung
antivir
treatment
make
valuabl
target
synthet
chemistri
panduratin
prototyp
member
famili
relat
cyclohexenyl
natur
product
isol
racem
mixtur
boesenbergia
rotunda
perenni
herb
found
southeast
asia
scheme
plant
use
tradit
medicin
treat
condit
diarrhea
asthma
indigest
dysenteri
mani
other
studi
shown
extract
antihiv
antibacteri
antifung
antitumor
activ
synthesi
propos
australian
research
group
reli
upon
da
cycloaddit
methyl
cinnam
e
ocimen
perform
high
pressur
condit
kbar
afford
regioisomer
panduratin
ratio
subsequ
oxid
alcohol
deriv
reduct
lialh
dmp
provid
aldehyd
branch
point
toward
final
target
addit
organolithium
reagent
deriv
bromobenzen
follow
dmp
oxid
gave
methoxymethyl
ether
mom
protect
keton
remov
mom
group
acid
methanol
cleanli
afford
panduratin
regiochem
outcom
da
cycloaddit
methyl
cinnam
e
ocimen
accord
analysi
base
comput
deriv
fmo
fig
align
larger
dien
homo
z
atom
coeffici
correspond
dienophil
lumo
coeffici
predict
format
ester
major
regioisom
wickerol
prove
highli
activ
type
influenza
viru
ic
natur
product
featur
uniqu
tetracycl
carbon
skeleton
compris
two
adjac
quaternari
carbon
seven
eight
stereocent
respect
two
quaternari
well
although
skeleton
wickerol
contain
fiveand
sixmemb
primari
ring
molecul
remark
strain
due
numer
syn
pentan
interact
despit
formid
lewi
acid
activ
found
solut
problem
jung
condit
employ
mixtur
albr
alm
catalyst
gave
desir
endoproduct
singl
diastereom
quaternari
neopentyl
stereocent
set
correct
simpl
induc
diastereoselect
presum
enon
approach
dien
via
endotransit
state
methyl
group
provid
less
steric
hindranc
siloxi
methyl
moieti
set
correct
configur
subsequ
modif
conduct
compound
led
ring
system
wickerol
complet
introduct
miss
methyl
group
methyl
group
dring
could
ad
complet
diastereoselect
exposur
methyl
lithiocyanocupr
presenc
bf
et
given
steric
hindranc
neopentyl
introduct
addit
synpentan
strain
remark
reaction
proceed
wickerol
obtain
sequenc
reaction
requir
insert
anoth
methyl
group
research
group
belgian
author
demonstr
dand
lcyclohexenylguanin
highli
potent
select
antiherp
viru
vzv
cmv
agent
activ
profil
similar
known
antivir
drug
acyclovir
ganciclovir
repres
potent
antivir
nucleosid
contain
sixmemb
carbohydr
mimic
ever
report
remark
antivir
activ
profil
enantiom
similar
enantioselect
synthesi
dand
lenantiom
compound
start
r
carvon
alreadi
describ
howev
synthesi
long
timeconsum
suit
prepar
larg
amount
final
product
need
full
biolog
evalu
fact
one
major
drawback
type
synthet
approach
need
high
amount
product
length
synthet
rout
caus
low
final
chemic
yield
belgian
author
set
novel
synthet
rout
overcom
problem
base
da
reaction
dienophil
danishefski
dien
presenc
hydroquinon
c
h
scheme
adduct
obtain
yield
mixtur
endoand
exoadduct
highli
function
adduct
sensit
acid
moistur
immedi
reduc
excess
lialh
give
triol
yield
reaction
involv
reduct
two
ester
group
concomit
rearrang
silyloxyenol
ether
enon
intermedi
reduc
reaction
triol
benzaldehyd
dimethyl
acet
presenc
paratoluensulfoni
acid
ptsa
room
temperatur
afford
benzyliden
acet
yield
introduct
purin
base
moieti
perform
reaction
mitsunobu
reaction
condit
gener
chloropurin
invers
configur
also
isol
final
acid
hydrolysi
gave
racem
overal
yield
start
exampl
report
typic
case
carbocycl
nucleosid
synthesi
carbanucleosid
modifi
nucleosid
methylen
group
replac
oxygen
atom
furanos
ring
due
absenc
glycosid
linkag
carbanucleosid
chemic
stabl
subject
phosphorylas
cleav
nglycosid
linkag
convent
nucleosid
mani
compound
class
potent
select
biolog
activ
identifi
includ
carbovir
abacavir
current
use
therapeut
antihiv
agent
import
aspect
antihiv
therapi
suppress
viral
replic
brain
regard
enhanc
lipophil
potenti
drug
like
advantag
modif
structur
fusion
carbocycl
heterocycl
ring
carbasugar
moieti
increas
lipophil
henc
access
central
nervou
system
major
reservoir
hiv
maintain
time
rigid
impos
doubl
bond
synthesi
carbocycl
nucleosid
contain
fuse
isoxazolin
ring
lack
methylen
group
side
chain
carbocycl
unit
suggest
new
class
analog
nucleosid
lack
methylen
group
side
chain
report
case
display
reduc
cytotox
synthet
rout
exploit
base
hda
cycloaddit
dien
transient
acyl
nitroso
moieti
afford
privileg
structur
synthesi
carbocycl
nucleosid
hda
cycloadduct
obtain
freshli
distil
cyclopentadien
quantit
trap
nitrosocarbonyl
benzen
gener
situ
good
yield
mild
oxid
benzonitril
oxid
phcno
bno
slight
excess
nmo
accord
report
procedur
scheme
hda
cycloadduct
found
excel
dipolarophil
toward
bno
addit
afford
two
regioisomer
cycloadduct
b
easili
isol
quantit
yield
chromatograph
separ
regioisomer
ratio
proper
tune
subsequ
synthet
step
done
scaleup
necessari
synthesi
nucleosid
due
amount
biolog
test
eas
detach
benzoyl
group
cycloadduct
b
achiev
naoh
meoh
treatment
room
temperatur
h
afford
fairli
stabl
hydroxylamin
reaction
conduct
ad
slight
excess
naoh
ad
portionwis
h
methanol
solut
cycloadduct
b
stir
complet
disappear
start
materi
hydrogenolyt
cleavag
nao
bond
hydroxylamin
perform
reaction
pdc
ethyl
acet
room
temperatur
h
henc
aminol
b
obtain
submit
transform
desir
nornucleosid
linear
construct
purin
pyrimidin
ring
synthesi
purinenucleosid
requir
two
step
first
one
condens
regioisomer
aminol
b
give
pyrimidin
deriv
type
b
condens
inde
difficult
step
mani
report
synthes
attain
low
yield
around
better
yield
b
achiev
increas
reaction
temperatur
gradual
boil
point
solvent
work
seal
tube
pyrimidin
deriv
b
obtain
yield
regioisomer
compound
convers
pyrimidin
deriv
b
chloropurin
compound
b
achiev
treatment
ethyl
orthoform
catalyt
amount
ptsoh
final
chlorin
replac
method
select
amin
conduct
upon
heat
meoh
solut
b
c
presenc
excess
nh
primari
secondari
amin
afford
adenin
deriv
b
yield
submit
biolog
test
compound
b
evalu
inhibitori
activ
wide
varieti
virus
includ
vaccinia
viru
vesicular
stomat
viru
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
respiratori
syncyti
viru
synthes
compound
show
specif
antivir
effect
howev
differ
regioisomer
nucleosid
note
regioisom
type
b
involv
phenyl
group
distal
heterocycl
base
display
better
respons
regioisom
type
proxim
phenyl
heterocycl
base
moreov
compound
evalu
antivir
activ
strain
iiib
strain
rob
cell
cultur
none
compound
show
inhibitori
activ
concentr
modest
antivir
activ
show
compound
could
like
link
lack
substrat
activ
cellular
andor
viral
nucleosid
kinas
altern
lack
recognit
compound
viral
dna
rna
polymeras
strategi
appli
synthesi
isoxazolinocarbocycl
nornucleosid
incorpor
anthracen
moieti
nitrosocarbonyl
intermedi
chemistri
varieti
analog
attain
start
alreadi
report
stereodefin
heterocycl
aminol
linear
construct
purin
heterocycl
ring
synthesi
hing
exo
select
cycloaddit
stabl
anthracenenitril
oxid
simpl
elabor
regiorisomer
cycloadduct
b
scheme
synthet
rout
scheme
appli
chloropurin
compound
b
prepar
select
nucleosid
primari
secondari
amin
deriv
b
initi
test
inhibitori
activ
varieti
virus
includ
hepat
b
c
human
papillomaviru
hpv
well
influenza
virus
type
b
modest
antivir
activ
observ
hepat
assay
activ
case
influenza
virus
almost
neglig
good
antivir
activ
found
compound
type
r
h
r
et
cellular
toxic
dose
test
case
hpv
report
sulfonyl
deriv
one
activ
compound
hpv
propos
literatur
fig
display
antivir
activ
alloster
mechan
hyperbol
competit
inhibitor
atpas
activ
also
inhibit
helicas
activ
fig
show
sulfonyl
structur
orang
shade
optim
dft
calcul
along
compound
r
h
r
et
overlap
obtain
root
mean
squar
rm
fit
aromat
moieti
see
nice
overlap
anthracen
naphthalen
aromat
ring
second
phenyl
ring
diphenyl
moieti
cross
purin
ring
direct
sulfonyl
group
posit
ethyl
group
locat
moreov
isoxazolin
ring
nice
overlap
amid
group
larger
activ
shown
compound
bear
naphthyl
residu
could
suggest
possibl
mechan
base
dnaintercal
isoxazolidinyl
polycycl
aromat
hydrocarbon
propos
dnaintercal
antitumor
agent
molecular
model
studi
structur
confirm
degre
bind
polycycl
aromat
residu
link
isoxazolin
heterocycl
ring
investig
complet
synthesi
isoxazolinocarbocycl
anthracen
nornucleosid
prepar
nitrosocarbonyl
chemistri
contain
uracil
residu
test
inhibitori
activ
virus
zoster
viru
hepat
b
c
activ
almost
neglig
case
remark
antivir
activ
found
specif
regioisom
cellular
toxic
dose
concentr
case
hpv
regard
hpv
complex
replic
machineri
begin
specif
bind
viral
dna
recruit
protein
rapidli
oligomer
hexam
around
nucleic
acid
display
helicas
activ
mechan
mind
bind
affin
uracil
deriv
evalu
protein
fig
flexibl
molecular
dock
uracil
deriv
receptor
give
dock
score
compar
even
higher
one
obtain
selfdock
crystallograph
inhibitor
fig
show
anchor
receptor
pocket
involv
interact
ppi
isoxazolin
ring
histidin
residu
anthracen
uracil
substitut
cyclopentanol
moieti
perfectli
complementari
pocket
involv
ppi
particular
anthracen
substitu
shade
hydrophob
pocket
involv
specif
interact
second
round
molecular
dock
calcul
conduct
specif
sequenc
dna
recogn
viral
strong
indic
obtain
specif
bind
dna
minor
groov
anticonfigur
uracil
anthracen
substitu
allow
backbon
adapt
minor
dna
groov
interact
uracil
ring
well
cyclopentan
hydroxyl
group
viral
dna
establish
heterobas
nucleic
acid
reason
inhibit
way
dna
replic
machineri
last
dock
calcul
carri
viral
helicas
protein
case
low
dock
score
along
lack
specif
interact
suggest
low
probabl
repres
biolog
target
upon
chang
nitril
oxid
structur
regioisomer
cycloadduct
b
bromonitril
oxid
easili
prepar
elabor
novel
class
uracil
nornucleosid
deriv
scheme
key
synthet
step
repres
reduct
bond
cleavag
unusu
doubl
ring
open
afford
aminol
intermedi
b
contain
structur
adapt
known
protocol
aminol
enter
linear
construct
uracil
ring
novel
nucleosid
b
found
structur
similar
potent
antivir
compound
brivudin
bvdu
molecular
model
dock
select
one
two
regioisomer
structur
promis
candid
antivir
test
due
nice
level
bind
thymidin
kinas
tk
enzym
involv
viru
replic
order
verifi
stabil
pose
better
simul
inducedfit
effect
ligand
enzym
optim
md
simul
perform
complex
b
within
tk
superimposit
b
bvdu
shown
fig
case
compound
stabil
pairwis
interact
nitrogen
basi
maintain
interact
lost
new
interact
observ
adapt
tk
bind
site
seem
driven
proxim
cn
group
side
chain
caus
chang
hydrogen
bond
network
found
cyclopentan
moieti
actual
oh
remain
contact
side
chain
oh
establish
interact
moreov
lone
pair
latter
hydroxyl
group
accept
hydrogen
bond
charg
side
chain
residu
turn
block
salt
bridg
convers
case
compound
one
two
hydrogen
bond
nucleobas
maintain
moreov
oh
group
cyclopentan
ring
interact
respect
furthermor
worthi
point
compound
b
compar
bvdu
lack
bromovinyl
chain
consequ
loss
relat
hydrophob
interact
might
exert
anchor
effect
pocket
enzym
shape
pursu
studi
antivir
compound
search
novel
small
molecul
potenti
biolog
activ
nucleosid
analog
prepar
found
moder
activ
human
herp
varicella
virus
strongli
activ
hpv
well
influenza
viru
take
advantag
synthet
protocol
reli
upon
nitrosocarbonyl
chemistri
pyridin
quinolin
hydroximoyl
chlorid
prepar
accord
literatur
procedur
scheme
select
aldehyd
convert
high
yield
correspond
oxim
follow
classic
method
latter
desir
hydroximoyl
chlorid
obtain
upon
chlorin
chlorin
ga
situ
gener
nitril
oxid
requir
present
case
sinc
none
nitril
oxid
hand
display
stabil
room
temperatur
possibl
solid
state
long
time
mild
oxid
nmo
conduct
onepot
presenc
requir
trap
dien
freshli
distil
cyclopentadien
afford
nitrosocarbonyl
hda
cycloadduct
deriv
obtain
bond
reduct
cleavag
test
varieti
virus
posit
result
obtain
case
respiratori
influenza
viru
major
compound
found
inact
singl
case
ec
valu
time
refer
compound
si
valu
must
increas
factor
one
time
hpv
find
nitrosocarbonyl
chemistri
valuabl
synthet
tool
achiev
remark
activ
target
viru
fleet
heterocycl
nitrosocarbonyl
deriv
correspond
nitril
oxid
work
shortcut
synthesi
scheme
synthet
strategi
base
hda
cycloaddit
situ
gener
nitril
oxid
follow
mild
reduct
cleavag
bond
cycloadduct
new
deriv
obtain
good
yield
result
vitro
antivir
test
indic
product
activ
hpv
viru
moreov
structur
evid
shine
light
futur
perspect
applic
pericycl
reaction
synthesi
biolog
activ
molecul
find
demonstr
synthet
methodolog
work
well
prepar
heterocycl
substitut
novel
compound
display
interest
promis
activ
virus
particular
hpv
result
clearli
show
compound
ineffici
herp
hepat
influenza
virus
except
emerg
compound
show
ec
valu
along
cc
valu
secondari
screen
demonstr
compound
found
less
effect
raft
cultur
primari
assay
hek
cell
ec
valu
higher
refer
compound
well
cc
valu
si
valu
howev
close
refer
ident
strategi
use
differ
start
materi
work
anoth
exampl
hpv
activ
molecul
new
adenin
deriv
prepar
chemistri
nitrosocarbonyl
intermedi
synthesi
reli
upon
function
adenin
insert
ester
moieti
transform
correspond
hydroxam
acid
scheme
oxid
conduct
situ
presenc
cyclopentadien
afford
hda
cycloadduct
elabor
give
target
nucleosid
analog
singl
product
display
select
high
activ
hpv
ec
number
synthet
carbocycl
nucleosid
furan
ring
replac
carbocycl
ring
found
display
import
therapeut
properti
us
fda
fact
approv
abacavir
treatment
entecavir
chronic
hbv
infect
fig
highli
oxygen
troponoid
identifi
lead
compound
hbv
infect
date
structurefunct
studi
molecul
limit
due
scarciti
synthet
method
prepar
success
adapt
oxidopyrilium
cycloadditionringopen
synthesi
appli
prepar
hbv
antagonist
shown
fig
analog
compound
contain
tricycl
spacer
display
interest
antivir
activ
interest
synthet
approach
system
shown
scheme
furan
ethyl
fumar
allow
react
afford
da
cycloadduct
reduc
lialh
give
diol
treatment
diol
benzyl
azidoform
allow
intramolecular
cycliz
give
deprotect
amino
group
aminol
condens
commerci
avail
give
adduct
standard
acidcatalyz
orthoform
cycliz
led
nucleosid
found
activ
coxsacki
viru
ec
cc
author
follow
similar
strategi
obtain
da
cycloadduct
scheme
furan
acrolein
even
low
yield
upon
function
cqc
doubl
bond
exo
regioisomer
diol
b
obtain
convert
endo
one
stereochem
invers
need
appli
mitsunobu
protocol
insert
ring
lead
nucleosid
b
good
yield
product
test
coxsacki
viru
display
follow
activ
ec
cc
ec
cc
group
czech
belgian
research
activ
involv
synthesi
novel
nucleosid
prepar
novel
homonucleosid
deriv
lock
west
conform
bridg
consist
annul
benzen
naphthalen
ring
illustr
crucial
step
synthesi
da
reaction
appropri
aryn
suitabl
furan
deriv
antivir
properti
novel
compound
studi
slight
activ
hcv
detect
sever
compound
although
larg
correl
cytotox
three
nucleosid
b
show
screen
result
suggest
weak
vitro
antivir
activ
coxsacki
viru
adenosin
concentr
show
inhibit
thymidin
concentr
show
inhibit
higher
concentr
concentr
led
highli
toxic
uridin
concentr
gave
best
result
show
inhibit
synthesi
shown
scheme
start
point
lactol
good
candid
wittig
reaction
allyltriphenylphosphonium
bromid
introduc
dien
function
screen
differ
base
potassium
tertbutoxid
kotbu
thf
gave
best
yield
trien
z
e
ratio
mixtur
trien
subject
oxid
ibx
oxid
furnish
trienon
yield
trienon
highli
unstabl
polymer
quickli
stand
vacuum
trienon
underw
intra
molecular
dielsald
imda
reaction
toluen
presenc
methylen
blue
seal
tube
give
hydrindenon
good
yield
hydrindenon
first
reduc
nabh
correspond
alcohol
ratio
one
could
oxid
back
protect
give
silyl
ether
epoxid
give
reduct
epoxid
newli
form
hydroxyl
group
acetyl
silyl
protect
remov
afford
convert
azid
chemistri
amin
linear
approach
adopt
synthes
target
molecul
reaction
amin
furnish
pyrimidin
miser
yield
standard
afford
adenin
deriv
convers
condens
freshli
prepar
isocyan
r
h
obtain
urea
b
subsequ
cycliz
uracil
deriv
timin
deriv
antivir
cycloaddit
reaction
repres
valuabl
class
react
intermedi
frequent
use
synthesi
antivir
compound
exampl
applic
chemistri
situ
gener
react
speci
alreadi
account
previou
page
nitril
oxid
work
synthesi
biolog
activ
molecul
role
introduct
suitabl
residu
necessari
display
correct
antivir
activ
start
materi
gener
react
speci
nitrosocarbonyl
intermedi
repres
key
intermedi
synthesi
target
compound
section
report
remark
exampl
use
frequent
use
synthesi
antivir
compound
review
success
employ
prepar
biolog
activ
molecul
vitro
data
also
report
one
frequent
use
azid
versatil
well
known
sinc
use
click
chemistri
well
prepar
triazol
valuabl
heterocycl
synthesi
biolog
activ
compound
organ
azid
belong
propargylallenyl
categori
dipol
sinc
discoveri
triazol
format
phenyl
azid
dimethyl
acetylenedicarboxyl
found
larg
success
construct
heterocycl
framework
core
structur
natur
bioactiv
compound
simpl
case
shown
scheme
treatment
sodium
azid
anhydr
dmf
gave
yield
methylthio
react
azidocompound
via
cycloaddit
reaction
anhydr
toluen
reflux
afford
mixtur
two
possibl
regioisom
regiosiom
obtain
well
known
literatur
addit
azid
unsymmetr
acetylen
determin
steric
electron
factor
gener
addit
tend
give
mainli
isom
electronwithdraw
group
electronreleas
group
thu
separ
regioisom
treatment
methanol
satur
ammonia
seal
react
vessel
c
led
carboacycl
nucleosid
carboacycl
nucleosid
synthes
yield
via
treatment
ch
onach
oh
room
temperatur
compound
prepar
compound
low
activ
vitro
parainfluenza
viru
type
reoviru
type
respect
mic
mcc
neither
iii
b
rod
activ
observ
cell
product
hand
uridin
deriv
type
synthes
via
cycloaddit
deriv
substitut
monoand
disubstitut
acetylen
scheme
antivir
activ
compound
hepat
viru
hav
mbb
cell
cultureadapt
strain
test
antivir
activ
note
concentr
test
cell
compound
type
reveal
highest
antivir
activ
seri
compound
type
reveal
high
activ
cell
use
amantadin
c
control
antivir
activ
result
reveal
compound
type
show
highest
effect
cell
compound
type
show
moder
activ
synthesi
antivir
evalu
seri
nucleosid
deriv
type
describ
agrofoglio
et
al
key
step
synthes
regioselect
huisgen
cycloaddit
reaction
use
either
coppercatalyz
azidealkyn
cycloaddit
cuaac
rutheniumcatalyz
azidealkyn
cycloaddit
ruaac
microwav
activ
start
tripl
bond
function
protect
nucleosid
structur
seri
substitut
azid
scheme
compound
among
synthes
seri
possess
activ
varicellazost
viru
human
cytomegaloviru
vaccinia
viru
cytostat
activ
determin
murin
leukemia
cell
human
tlymphocyt
cell
cervix
carcinoma
cell
compound
also
evalu
wide
panel
rna
virus
includ
vesicular
stomat
viru
influenza
virus
type
b
mdck
cell
cultur
viru
sindbi
viru
punta
toro
viru
vero
cell
cultur
vesicular
stomat
coxsacki
respiratori
syncyti
viru
howev
specif
antivir
effect
cellular
activ
observ
like
impli
compound
abl
penetr
cell
synthes
compound
show
activ
sever
dna
virus
micromolar
rang
wherea
exhibit
antivir
activ
interest
note
regioisom
found
inact
wide
panel
virus
display
toxic
order
design
compound
significantli
increas
potenc
necessari
studi
phosphoryl
human
viral
kinas
process
would
greatli
aid
cocryst
structur
best
compound
bound
enzym
activ
site
also
interest
investig
properti
monophosphoryl
deriv
thymidyl
synthas
triphosphoryl
deriv
viral
cellular
dna
polymeras
reveal
mechan
biolog
action
coppercatalyz
cycloaddit
reaction
azidoristocetin
aglycon
variou
propargyl
glycosid
use
prepar
new
sugar
deriv
ristocetin
compound
found
activ
gramposit
bacteria
show
favor
antivir
activ
subtyp
influenza
viru
guanosin
deoxi
analog
readili
convert
allyl
deriv
type
upon
diazot
tbuono
tmsn
yield
azido
deriv
type
scheme
american
belgian
research
previous
analyz
solvent
depend
azid
tetrazol
equilibrium
azidopurin
nucleosid
contrast
allyl
azido
nucleosid
appear
exist
predominantli
azido
form
rel
independ
solvent
polar
consist
presenc
azido
function
neat
azid
display
promin
ir
band
cm
screen
condit
ligat
azido
nucleosid
alkyn
show
cucl
tbuohh
optim
yield
nucleosid
yield
remov
silyl
group
et
n
follow
deallyl
phso
napd
pph
gave
triazolylinosin
nucleosid
product
desilyl
biolog
assay
two
triazolyl
adenosin
analog
demonstr
pronounc
antiprolif
activ
human
ovarian
colorect
carcinoma
cell
cultur
evalu
antivir
activ
broad
spectrum
dna
rna
virus
triazolylinosin
deriv
show
modest
inhibitori
activ
cytomegaloviru
compound
howev
display
somewhat
pronounc
activ
anticmv
ec
effici
synthesi
new
seri
polyhydroxyl
dibenzyl
alkylphosphon
acycl
nucleotid
analog
type
describ
belgian
polish
research
start
dibenzyl
polyhydroxi
alkylphosphon
select
alkyn
microwav
irradi
scheme
select
odibenzylphosphon
acyclonucleotid
transform
respect
phosphon
acid
compound
evalu
vitro
activ
broad
varieti
dna
rna
virus
cytostat
activ
murin
leukemia
human
tlymphocyt
cem
human
cervix
carcinoma
hela
cell
compound
tymin
exhibit
antivir
activ
influenza
subtyp
ec
cpe
score
ec
author
previou
work
prepar
new
seri
acetamido
methylphosphon
type
acycl
nucleotid
analog
synthes
diethyl
methylphosphon
via
azid
follow
cycloaddit
select
alkyn
deriv
natur
nucleobas
mimet
scheme
compound
test
antivir
activ
dna
rna
virus
well
cytostat
activ
cytotox
among
test
compound
acetamido
methylphosphon
bear
methylimidazol
substitu
show
activ
vesicular
stomat
viru
ec
hela
cell
cultur
nucleosid
analog
commonli
use
hivaid
therapi
first
line
therapeut
mani
tumor
type
enter
membran
nucleosid
analog
phosphoryl
intracellular
nucleosid
kinas
activ
mono
di
triphosph
drug
resist
nucleosid
analog
refer
nucleosid
transport
defici
reduc
nucleosid
kinas
activ
overexpress
multidrug
resist
protein
modif
apoptot
pathway
conceiv
strategi
avoid
resist
use
prephosphoryl
nucleosid
directli
drug
thu
bypass
intracellular
phosphoryl
howev
nucleosid
triphosph
ntp
poorli
intern
cell
attempt
get
around
problem
mask
phosphat
group
turn
phosphat
ester
success
recent
fulli
substitut
diand
triphosph
ester
becom
unstabl
difficulti
develop
lipophil
ntp
prodrug
aris
due
hydrolyt
instabl
pyrophosph
bond
natur
ntp
bond
kinet
stabl
due
neg
charg
slow
cleavag
nucleophil
altern
lipophil
prodrug
approach
could
use
drug
deliveri
system
liposom
nanogel
nanoparticl
could
potenti
solv
problem
poor
cell
absorpt
ntp
sio
nanoparticl
repres
simpl
versatil
method
prepar
sio
dntp
conjug
sever
exampl
nucleosid
analog
origin
approv
antivir
agent
shown
display
promis
anticanc
properti
thu
conjug
antivir
phosphoryl
nucleosid
analog
may
also
possess
potenti
antitumor
activ
russian
research
prepar
triphosph
antihiv
nucleosid
drug
lamivudin
zalcitabin
phosphoramid
group
obtain
conjug
sio
nanoparticl
sio
dntp
via
cu
catalyz
azidealkyn
cycloaddit
assess
antivir
cytotox
properti
scheme
show
synthet
rout
pivot
step
repres
insert
tripl
bond
phosphoryl
deriv
give
undergo
cycloaddit
azid
afford
final
compound
conjug
phosphoryl
lamivudin
dideoxycytidin
zalcitabin
show
higher
potenc
parent
nucleosid
conjug
phosphoryl
azidothymidin
azt
less
activ
parent
nucleosid
probabl
replac
azido
group
ring
result
show
opportun
use
sio
nanoparticl
transport
deliv
phosphoryl
nucleosid
cell
order
increas
effici
antivir
anticanc
drug
nonoblig
chain
termin
nucleosid
linear
substitu
azido
ethynyl
group
posit
repres
import
class
compound
antivir
discoveri
particularli
hcv
hiv
aztderiv
potent
inhibitor
gaug
medicin
chemistri
impact
function
linear
substitu
possibl
gener
novel
antivir
nucleosid
scaffold
azidealkyn
cycloaddit
reaction
azt
investig
fig
show
structur
famili
thymidin
triazol
deriv
antivir
screen
identifi
triazol
analog
moder
activ
inhibit
mm
andor
influenza
viru
inhibit
mm
none
activ
west
nile
viru
hcv
result
suggest
linear
azido
group
adrt
may
essenti
target
bind
chemic
manipul
could
larg
compromis
antivir
potenc
azidotriazol
deriv
found
potent
antihbv
agent
use
multival
carbohydr
compound
block
cellsurfac
lectin
receptor
promis
strategi
inhibit
entri
pathogen
cell
could
lead
discoveri
novel
antivir
agent
one
main
problem
approach
howev
difficult
make
compound
adequ
size
multival
mimic
natur
system
virus
hexaki
adduct
fulleren
use
build
block
regard
maintain
globular
shape
time
allow
control
size
multival
watersolubl
tridecafulleren
decor
peripher
carbohydr
subunit
socal
superbal
prepar
collabor
sever
european
research
group
could
synthes
effici
hexaki
adduct
fulleren
one
step
use
coppercatalyz
azidealkyn
cycloaddit
click
chemistri
fig
infect
assay
show
superbal
potent
inhibitor
cell
infect
artifici
ebola
viru
halfmaximum
inhibitori
concentr
subnanomolar
rang
previou
exampl
seen
applic
cuaac
methodolog
synthesi
antivir
compound
consider
attent
direct
chemic
modifi
nucleic
acid
robust
function
group
order
alter
properti
sinc
breakthrough
cuaac
sever
report
describ
synthesi
properti
novel
triazolemodifi
nucleic
acid
deriv
potenti
downstream
dnaand
rnabas
applic
review
focu
highlight
repres
novel
nucleic
acid
molecular
structur
synthes
via
click
azidealkyn
cycloaddit
mani
deriv
show
compat
variou
applic
involv
enzymat
transform
nucleic
acid
hybrid
molecular
tag
purif
gene
silenc
detail
applic
found
manuscript
chemistri
triazol
seem
realli
promis
futur
develop
antivir
anticanc
compound
field
macromolecular
structur
distinct
welldefin
glycopolym
deciph
biolog
role
natur
bioactiv
polysaccharid
prepar
fucos
monom
chemic
synthes
decor
specif
sulfat
pattern
includ
unsulf
monosulf
disulf
trisulf
group
fig
six
fucoidanmimet
glycopolym
success
fabric
microwav
mw
assist
ringopen
metathesi
polymer
emuls
system
three
glycopolym
associ
exhibit
better
inhibitori
effect
viru
glycopolym
monosulf
group
effect
viru
find
would
promot
develop
novel
antiinfluenza
viru
drug
base
natur
fucoidan
anoth
class
extens
use
synthesi
antivir
compound
constitut
nitron
nitron
arguabl
use
tool
abil
gener
nitrogenand
oxygenbas
function
introduc
chiral
center
stereoselect
first
prepar
beckmann
sever
method
known
prepar
apt
fit
synthet
requir
use
plan
synthes
constitut
valuabl
entri
isoxazolidin
heterocycl
ring
remark
altern
sugar
moieti
nucleosid
mimic
spacer
natur
compound
facil
prepar
varieti
substitu
place
structur
determin
success
reactiv
speci
synthesi
new
biolog
activ
compound
among
numer
exampl
report
literatur
worth
mention
use
unconvent
nitron
bear
phosphon
substitu
lead
new
class
truncat
phosphon
oxazanucleosid
phosphon
nitron
undergo
cycloaddit
reaction
ethyl
thf
reflux
afford
isoxazolidin
minor
compon
diasteroisomer
mixtur
yield
upon
adapt
protocol
uracil
thymin
insert
isoxazolidin
skeleton
give
final
compound
scheme
biolog
test
indic
anom
inhibit
revers
transcriptas
avian
moloney
viru
amv
human
tlymphotrop
viru
hiv
particular
deriv
promis
compound
act
abelson
murin
leukemia
viru
hiv
concentr
nm
respect
level
inhibitori
activ
product
toward
hiv
higher
tenofovir
similar
azt
moreov
compound
show
cytotox
accord
mt
assay
cycloaddit
vinyl
acet
led
also
diasterom
type
yield
insert
thymin
led
nucleosid
b
found
inhibit
complet
revers
transcriptas
amv
hiv
concentr
nm
level
compar
tenofovir
nm
lower
azt
nm
moreov
mt
assay
indic
low
toxic
cc
comparison
azt
cc
mani
applic
phosphon
nitron
review
process
studi
mechanist
point
view
cycloaddit
fact
show
complet
regioselect
nearli
exclus
ci
stereoselect
p
calcul
conduct
ration
regioand
stereochem
outcom
novel
seri
type
b
synthes
via
cycloaddit
reaction
nmethylc
diethoxyphosphoryl
nitron
nsubstitut
naphthalimid
acrylamid
b
prepar
amin
b
upon
function
acryloyl
chlorid
presenc
triethylamin
scheme
cisand
transisoxazolidin
phosphon
obtain
assess
antivir
activ
broad
rang
dna
rna
virus
isoxazolidin
exhibit
highest
activ
ec
toward
cytomegaloviru
compound
cisand
well
cisand
found
potent
hsv
vaccinia
virus
ec
rang
antiprolif
evalu
obtain
isoxazolidin
reveal
promis
activ
toward
test
cancer
cell
line
ic
rang
anoth
class
found
attent
synthesi
nucleosid
analog
nitril
oxid
although
less
use
synthesi
nucleosid
high
instabl
difficulti
prepar
case
report
choic
proper
substitu
solv
select
problem
facilit
access
biolog
activ
molecul
seri
novel
isoxazolinelink
pseudodisaccharid
deriv
regiospecif
synthes
cycloaddit
reaction
sugarderiv
nitril
oxid
good
yield
nitril
oxid
prepar
start
aldehyd
upon
convers
correspond
oxim
chlorin
nchlorosuccinimid
nc
follow
situ
gener
presenc
suitabl
dipolarophil
scheme
structur
compound
character
nmr
spectroscopi
ms
spectrometri
confirm
xray
crystallograph
analysi
glycosidas
inhibitori
activ
compound
determin
hydrolyt
reaction
glycosidas
use
acarbos
control
howev
compound
show
select
moder
inhibit
inhibit
concentr
ml
hivrt
antitumor
activ
also
preliminarili
evalu
type
cycloadduct
exhibit
potent
inhibitori
activ
hivrt
introduct
second
heteroatom
furanos
ring
would
result
sever
new
class
nucleosid
analog
presenc
multiheteroatom
fivememb
ring
desir
retain
requir
conform
recognit
nucleosid
target
enzym
revers
transcriptas
use
oxygen
sulfur
atom
produc
sever
diheteroatomsubstitut
analog
dioxolanyl
oxathiolanyl
nucleosid
potent
viru
inhibitor
synthet
challeng
introduc
oxygen
nitrogen
fivememb
ring
keep
glycosid
bond
compound
dihydroisoxazolidin
display
mutual
induct
effect
two
heteroatom
exert
sever
desir
properti
first
nitrogen
atom
becom
less
basic
prevent
proton
therefor
synthes
compound
expect
stabl
physiolog
ph
second
oxygen
atom
may
also
becom
less
nucleophil
make
glycosid
bond
resist
acid
hydrolysi
use
nitril
oxid
prepar
antivir
deriv
via
cycloaddit
reaction
repres
valuabl
method
achiev
target
nucleosid
structur
defin
compound
spacer
often
play
key
role
recognit
biolog
activ
outcom
cycloaddit
reaction
offer
varieti
method
synthesi
nucleosid
particular
regard
spacer
structur
within
frame
cyclic
spacer
given
frequent
encount
fiveand
sixmemb
ring
structur
cyclobutan
moieti
receiv
consider
attent
due
broad
spectrum
antivir
anticanc
compound
discov
moreov
cyclobutan
amino
acid
dipeptid
found
natur
interest
properti
antibiot
antivir
cyclobutan
structur
unit
easili
prepar
photochem
cycloaddit
reaction
use
suitabl
precursor
bear
preform
cyclobutan
ring
absolut
chiral
rais
chiral
precursor
obtain
natur
sourc
use
chiral
catalyst
function
carbocycl
ring
also
challeng
task
crucial
synthesi
polyfunction
nucleosid
amino
acid
search
therapeut
agent
hsv
hiv
much
attent
focus
prepar
analog
natur
nucleosid
antimetabolit
analog
modifi
carbohydr
portion
molecul
spacer
base
portion
examin
molecular
model
suggest
cyclobutan
ring
might
serv
surrog
oxetan
ring
oxetanocin
observ
led
synthesi
racem
carbocycl
analog
oxetanocin
compound
exhibit
broadspectrum
activ
hsv
hiv
scheme
consid
promis
agent
aid
treatment
synthesi
analog
mani
prepar
method
optic
activ
cyclobutan
deriv
develop
report
synthes
resort
racem
enantiomer
pure
substitut
cyclobutanon
key
intermedi
furthermor
nucleosid
strategi
may
reli
converg
synthesi
linear
approach
scheme
tertbutyldimethylsilyl
oxi
methyl
one
irradi
nm
intermedi
obtain
result
photochem
ring
closur
synthet
elabor
led
protect
cyclobutaneamin
start
point
linear
construct
adenin
guanin
respect
afford
compound
repres
simpl
exampl
way
compound
easili
obtain
mani
approach
report
literatur
regard
prepar
antivir
compound
also
synthesi
amino
acid
peptid
biolog
activ
molecul
